HORIZON

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dimebon in Patients with Mild-To-Moderate Huntington Disease

Under the direction of Karl Kieburtz, MD, MPH, Principal Investigator (University of Rochester), and Bernhard Landwehrmeyer, MD, co-Principal Investigator (University of Ulm), the Huntington Study Group (HSG), and the European Huntington’s Disease Network (EHDN) are conducting a global collaborative multi-center, randomized, double-blind, placebo-controlled study of Dimebon in individuals with mild-to-moderate Huntington disease (HD). The purpose of the study is to assess the safety and efficacy of Dimebon 60 mg per day, when taken over a period of 6 months. Efficacy is determined by exploring whether or not there is an effect on cognitive (thinking) abilities and overall functioning in people with HD. The study will also evaluate other HD symptoms including behavioral and motor (movement) symptoms. Approximately 60 research centers across North America, Europe, and Australia, will enroll approximately 350 individuals.

Dimebon is an experimental drug. Research has shown that Dimebon might be effective in preventing the death of brain cells in animals and improving thinking and memory in Alzheimer disease. Results of a HD study in the United States and United Kingdom showed that Dimebon 60mg per day was safe and well tolerated and suggested that Dimebon may improve cognition (thinking abilities) in individuals with HD.

This study is being sponsored by Medivation, Inc in collaboration with Pfizer, Inc.

For more information: call the Huntington Study Group toll-free number (United States and Canada): 1-800-487-7671

For more information: call the European Huntington’s Disease Network: +44 7791 985313 or fax +49 731 5006 3082 or visit the website at www.euro-hd.net

Please see the HORIZON participating site list. HORIZON research sites and their contact information will be added frequenly to this list. Please check back. Thank you.

last updated: February 2010


Home Clinical Research Clinical Trials/Observational Studies in Progress 2CARE COHORT CREST-E DIMOND HART HORIZON PHAROS PREDICT-HD PREQUEL RESPOND-HD Completed Clinical Trials HSG Research Sites Request for Proposals About Us HSG Overview HSG Executive Committee HSG Working Groups Standing HSG Committees Becoming an HSG Research Site Education Resources Login FAQ's Clinical Care UHDRS Links Publications News & Events Events & Upcoming Meetings PSG/HSG Symposium Huntington Disease Clinical Research Symposium Giving Contact Us	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dimebon in Patients with Mild-To-Moderate Huntington Disease Under the direction of Karl Kieburtz, MD, MPH, Principal Investigator (University of Rochester), and Bernhard Landwehrmeyer, MD, co-Principal Investigator (University of Ulm), the Huntington Study Group (HSG), and the European Huntington’s Disease Network (EHDN) are conducting a global collaborative multi-center, randomized, double-blind, placebo-controlled study of Dimebon in individuals with mild-to-moderate Huntington disease (HD). The purpose of the study is to assess the safety and efficacy of Dimebon 60 mg per day, when taken over a period of 6 months. Efficacy is determined by exploring whether or not there is an effect on cognitive (thinking) abilities and overall functioning in people with HD. The study will also evaluate other HD symptoms including behavioral and motor (movement) symptoms. Approximately 60 research centers across North America, Europe, and Australia, will enroll approximately 350 individuals. Dimebon is an experimental drug. Research has shown that Dimebon might be effective in preventing the death of brain cells in animals and improving thinking and memory in Alzheimer disease. Results of a HD study in the United States and United Kingdom showed that Dimebon 60mg per day was safe and well tolerated and suggested that Dimebon may improve cognition (thinking abilities) in individuals with HD. This study is being sponsored by Medivation, Inc in collaboration with Pfizer, Inc. For more information: call the Huntington Study Group toll-free number (United States and Canada): 1-800-487-7671 For more information: call the European Huntington’s Disease Network: +44 7791 985313 or fax +49 731 5006 3082 or visit the website at www.euro-hd.net Please see the HORIZON participating site list. HORIZON research sites and their contact information will be added frequenly to this list. Please check back. Thank you. Related Documents: HSG Presss Release: HSG and EHDN Begin Joint Phase III Study in Huntington Disease (HD) February 2010 HORIZON Participating Site List May 2009 HORIZON Brochure May 2009 HORIZON Study Site List Related Links: HORIZON Trial Web Site July 2009 Medivation Press Release June 2009 - Interview with the HORIZON Principal Investigator, Karl Kieburtz - By Marsha Miller, PhD Clinical Trials.Gov last updated: February 2010